| Title |
Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment
|
|---|---|
| Published in |
OncoTargets and therapy, May 2017
|
| DOI | 10.2147/ott.s130371 |
| Pubmed ID | |
| Authors |
Yingyun Shi, Renbing Jia, Xianqun Fan |
| Abstract |
Basal cell carcinoma (BCC) is a common malignant tumor throughout the world. One of the known risk factors of BCC is intense exposure to ultraviolet radiation. More than 50% of BCCs of the eyelid initially occur on the lower lid. The gold standard of diagnosis of BCC is histopathology. Treatment options for BCC consist of surgery, vismodegib, radiotherapy and imiquimod. Surgical excision using Mohs micrographic surgery or wide surgical excision with frozen section margin control is the first consideration for treatment of periocular BCC. Eyelid reconstruction should be carefully considered as both function and esthetic outcome in patients are important after clear excision of tumors. Exenteration is considered in the case of extensive orbital invasion or high-risk aggressive tumors in order to reduce the rate of recurrence. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 131 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Unknown | 130 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 23 | 18% |
| Other | 15 | 11% |
| Student > Master | 10 | 8% |
| Student > Postgraduate | 8 | 6% |
| Researcher | 5 | 4% |
| Other | 14 | 11% |
| Unknown | 56 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 62 | 47% |
| Biochemistry, Genetics and Molecular Biology | 3 | 2% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
| Unspecified | 2 | 2% |
| Nursing and Health Professions | 2 | 2% |
| Other | 4 | 3% |
| Unknown | 56 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 July 2018.
All research outputs
#1,981,822
of 25,382,440 outputs
Outputs from OncoTargets and therapy
#43
of 3,016 outputs
Outputs of similar age
#36,909
of 324,557 outputs
Outputs of similar age from OncoTargets and therapy
#4
of 77 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,557 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 77 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.